HOUSTON & HYDERABAD, India & BASEL, Switzerland--(BUSINESS WIRE)--Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), and Coya Therapeutics, Inc.

休斯顿、印度海得拉巴和瑞士巴塞尔——（商业新闻短讯）——Dr。Reddy's Laboratories SA是Reddy's Laboratories Ltd.（BSE:500124，NSE:DRREDDY，NYSE:RDY，NSEIFSC:DRREDDY，及其子公司统称为“Dr.Reddy's”）和Coya Therapeutics，Inc.的全资子公司。

(NASDAQ: COYA) (“Coya”), today announced that they have entered into a development and license agreement (the “Agreement”) for the development and commercialization of COYA 302, an investigational combination therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS)..

（纳斯达克股票代码：COYA）（“COYA”）今天宣布，他们已经就COYA 302的开发和商业化签署了开发和许可协议（“协议”），COYA 302是一种用于治疗肌萎缩侧索硬化症（ALS）的研究性联合疗法。。

Under the terms of the Agreement, Coya has granted Dr. Reddy’s an exclusive license to commercialize COYA 302, a proprietary co-pack kit containing combination of low dose IL-2 and CTLA-4 Ig (abatacept) in the United States, Canada, the European Union and the United Kingdom for ALS. This Agreement is in addition to the in-licensing agreement with Dr.

根据协议条款，Coya已授予Reddy博士商业化Coya 302的独家许可，Coya 302是一种专有的co-pack试剂盒，在美国，加拿大，欧盟和英国用于ALS，含有低剂量IL-2和CTLA-4 Ig（abatacept）的组合。该协议是与Dr.的in-licensing协议的补充。

Reddy’s signed in early 20231. Coya retains the right to commercialize COYA 302 for patients with amyotrophic lateral sclerosis (ALS) in Japan, Mexico, and each country in South America. Coya will have responsibility for the clinical development of COYA 302 and for seeking regulatory approval for COYA 302 for patients with ALS in the United States..

雷迪于20231年初签约。Coya保留在日本、墨西哥和南美每个国家为肌萎缩侧索硬化症（ALS）患者商业化Coya 302的权利。Coya将负责Coya 302的临床开发，并负责为美国ALS患者寻求Coya 302的监管批准。。

Dr. Reddy’s will make a USD 7.5 million upfront payment to Coya. Upon the first FDA acceptance of an investigational new drug (IND) application for COYA 302 for the treatment of ALS, Dr. Reddy’s will pay Coya an additional USD 4.2 million. Upon dosing of the first patient in the first Phase 2 trial of COYA 302 for the treatment of ALS in the United States, Dr.

Reddy博士将向Coya支付750万美元的预付款。在FDA首次接受COYA 302用于治疗ALS的研究性新药（IND）申请后，Reddy博士将向COYA额外支付420万美元。在美国COYA 302治疗ALS的第一阶段2试验中，第一名患者给药后。

Reddy’s will pay Coya an additional USD 4.2 million. Coya anticipates that the IND filing will be made in the first half of 2024. The Agreement also includes development and regulatory milestones up to USD 40 million should all such development and regulatory milestones be achieved. Additionally, Coya is eligible to receive sales-based milestone payments of up to USD 677.25 million linked to tiers of cumulative net sales being achieved over several years (over the term of the agreement subject to product commercial exclusivity).

Reddy's将向Coya额外支付420万美元。Coya预计IND将于2024年上半年提交。该协议还包括开发和监管里程碑，如果实现所有此类开发和监管里程碑，则最高可达4000万美元。此外，Coya有资格获得高达67725万美元的基于销售的里程碑付款，该付款与几年内（在协议期限内，受产品商业排他性限制）实现的累积净销售额相关。

In addition, Dr. Reddy’s will pay Coya royalties based on a percentage net sales of COYA 302 ranging from low to middle teens. Coya is not a related party to Dr. Reddy’s or its promoters/promoter group..

此外，Reddy博士将根据Coya 302的净销售额百分比（从低到中青少年）向Coya支付版税。Coya不是Reddy博士或其发起人/发起人小组的关联方。。

Marc Kikuchi, Chief Executive Officer of Dr. Reddy’s North America, said: “Patients with ALS, commonly known as Lou Gehrig’s disease, have very few treatment options. We are pleased to partner with Coya Therapeutics on this investigational therapy which may have a unique place in treating patients with this progressive neurodegenerative disease.

Reddy博士北美区首席执行官Marc Kikuchi说：“ALS患者（通常称为Lou Gehrig病）的治疗选择很少。我们很高兴与Coya Therapeutics合作进行这项研究性治疗，这可能在治疗这种进行性神经退行性疾病患者方面具有独特的地位。

With this promising biologic product, we hope to reach many more patients around the world in keeping with our aim of serving over 1.5 billion patients by 2030. Dr. Reddy’s biosimilars/biologics business is part of our key strategic initiatives expected to drive both near-term and long-term growth.”.

有了这种有前途的生物产品，我们希望能够接触到世界各地更多的患者，以实现到2030年为超过15亿患者提供服务的目标。Reddy博士的生物仿制药/生物制剂业务是我们关键战略计划的一部分，预计将推动近期和长期的增长。”。

Dr. Howard Berman, Chief Executive Officer of Coya observed: “The Coya team is delighted to enter this exciting partnership with Dr. Reddy’s, a world class organization that defines excellence in innovation and commercialization. While the agreement provides the financial resources to execute on the Phase 2 clinical program for COYA 302 in ALS, the strategic value of the partnership contributes much more than capital.

Coya首席执行官霍华德·伯曼博士表示：“Coya团队很高兴与。Reddy’s是一家世界级的组织，它定义了创新和商业化方面的卓越。虽然该协议为COYA 302在ALS的第二阶段临床计划提供了财政资源，但该合作伙伴关系的战略价值远大于资本。

We will benefit from and leverage Dr. Reddy’s manufacturing expertise and growing commercial infrastructure both in the USA and worldwide as we plan together for the future of COYA 302 in ALS, a devastating disease with a high unmet need.”.

我们将受益于并利用Reddy博士在美国和全球范围内的制造专业知识和不断增长的商业基础设施，共同规划COYA 302在ALS中的未来，这是一种毁灭性疾病，需求尚未得到满足。”。

COYA 302 was developed out of the multi-year translational research collaboration between Coya and Houston Methodist in the laboratory of Dr. Stanley Appel, an internationally renowned researcher and clinician. Houston Methodist is one of the leading hospital and academic research facilities.

COYA 302是由COYA和休斯顿卫理公会（Houston Methodist）在国际著名研究人员和临床医生斯坦利·阿佩尔（Stanley Appel）博士的实验室进行的多年转化研究合作开发而成。休斯顿卫理公会是领先的医院和学术研究机构之一。

About Coya 302:

关于Coya 302：

COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. COYA 302 is comprised of proprietary low dose interleukin-2 (LD IL-2) and CTLA-4 Ig, and is being developed for subcutaneous administration for the treatment of patients with ALS.

COYA 302是一种研究性和专有的生物联合疗法，具有双重免疫调节作用机制，旨在增强调节性T细胞（Tregs）的抗炎功能并抑制活化的单核细胞和巨噬细胞产生的炎症。COYA 302由专有的低剂量白细胞介素-2（LD IL-2）和CTLA-4 Ig组成，正在开发用于皮下给药以治疗ALS患者。

These mechanisms may have additive or synergistic effects..

这些机制可能具有累加或协同效应。。

In February of 2023 Coya announced results from a proof-of-concept, open-label clinical study evaluating LD IL-2 and CTLA-4 Ig in small cohort of patients with ALS, conducted at the Houston Methodist Research Institute (Houston, Texas) by Stanley Appel, M.D., Jason Thonhoff, M.D., Ph.D., and David Beers, Ph.D.

2023年2月，Coya宣布了由Stanley Appel，M.D.，Jason Thonhoff，M.D.，和David Beers，Ph.D.在休斯顿卫理公会研究所（德克萨斯州休斯顿）进行的一项评估ALS患者小群LD IL-2和CTLA-4 Ig的概念验证，开放标签临床研究的结果。

This study was the first-of-its-kind evaluating this dual-mechanism immunotherapy for the treatment of ALS. Patients in the study received investigational treatment for 48 consecutive weeks and were evaluated for safety and tolerability, Treg function, serum biomarkers of oxidative stress and inflammation, and clinical functioning as measured by the ALSFRS-R scale..

这项研究是首次评估这种用于治疗ALS的双重机制免疫疗法。该研究中的患者连续48周接受研究性治疗，并通过ALSFRS-R量表评估其安全性和耐受性，Treg功能，氧化应激和炎症的血清生物标志物以及临床功能。。

During the 48-week treatment period, the therapy was well tolerated. The most common adverse event was mild injection-site reactions. No patient discontinued the study, and no deaths or other serious adverse events were reported.

在48周的治疗期间，治疗耐受性良好。最常见的不良事件是轻微的注射部位反应。没有患者停止研究，也没有死亡或其他严重不良事件的报告。

Patients' disease progression was measured using the ALSFRS-R scale, a validated rating tool for monitoring the progression of disability in patients with ALS. The mean (±SD) ALSFRS-R scores at week 24 (33.75 ±3.3) and week 48 (32 ±7.8) after initiation of treatment were not statistically different compared to the ALSFRS-R score at baseline (33.5 ±5.9), suggesting significant amelioration in the progression of the disease over the 48-week treatment period..

使用ALSFRS-R量表测量患者的疾病进展，ALSFRS-R量表是一种经过验证的评估工具，用于监测ALS患者的残疾进展。治疗开始后第24周（33.75±3.3）和第48周（32±7.8）的平均（±SD）ALSFRS-R评分与基线时的ALSFRS-R评分（33.5±5.9）相比无统计学差异，表明48周治疗期间疾病进展显着改善。。

Treg suppressive function, expressed as percentage of inhibition of proinflammatory T cell proliferation, showed a statistically significant increase over the course of the treatment period and was significantly reduced at the end of the 8-week washout post-treatment period. Treg suppressive function at 24 weeks (79.9±9.6) and 48 weeks (89.5±4.1) were significantly higher compared to baseline (62.1±8.1) (p<0.01), suggesting enhanced and durable Treg suppressive function over the course of treatment.

Treg抑制功能表示为促炎性T细胞增殖抑制的百分比，在治疗期间显示出统计学上显着的增加，并且在治疗后8周的清除期结束时显着降低。24周（79.9±9.6）和48周（89.5±4.1）的Treg抑制功能明显高于基线（62.1±8.1）（p＜0.01），表明治疗过程中Treg抑制功能增强且持久。

In contrast, Treg suppressive function (mean ±SD) was significantly decreased at the end of the 8-week washout period compared to end-of-treatment at week 48 (70.3±8.1 vs. 89.5±4.1, p <0.05)..

相比之下，与第48周治疗结束时相比，8周清除期结束时Treg抑制功能（平均值±SD）显着降低（70.3±8.1比89.5±4.1，p＜0.05）。。

The study also evaluated serum biomarkers of inflammation, oxidative stress, and lipid peroxides. The available data up to 16 weeks after initiation of treatment suggest a decrease of these biomarker levels, which is consistent with the observed enhancement of Treg function. The evaluation of the full biomarker data is ongoing..

该研究还评估了炎症，氧化应激和脂质过氧化物的血清生物标志物。治疗开始后16周的可用数据表明这些生物标志物水平降低，这与观察到的Treg功能增强一致。正在对完整的生物标志物数据进行评估。。

Coya 302 is an investigational product not yet approved by the U.S. Food and Drug Administration or any other regulatory agency.

Coya 302是一种尚未获得美国食品和药物管理局或任何其他监管机构批准的研究产品。

About Dr. Reddy’s biosimilars/biologics programme:

关于Reddy博士的生物仿制药/生物制剂计划：

A part of its key strategic initiatives, it is expected to drive both near-term and long-term growth. Over the last 20 years, the team has developed into a fully integrated organisation with robust capabilities in the development, manufacture and commercialisation of a range of biosimilar products in oncology and immunology.

作为其关键战略举措的一部分，预计它将推动近期和长期的增长。在过去的20年中，该团队已发展成为一个全面整合的组织，在肿瘤学和免疫学领域的一系列生物仿制药产品的开发，制造和商业化方面具有强大的能力。

The portfolio currently has six commercial biosimilar products marketed in India and over 27 Emerging Markets. In addition, there are several products in the pipeline in oncology and auto-immune diseases in various stages of development for global launches across regulated as well as emerging markets.

该投资组合目前有六种商业生物仿制药产品在印度和27个新兴市场销售。此外，在不同的发展阶段，有几种肿瘤学和自身免疫疾病产品正在筹备中，以便在受监管市场和新兴市场进行全球发布。

Coya has successfully completed the Phase 2 study and initiated the Phase 3 study of DRL_TC, its proposed biosimilar of tocilizumab via both the subcutaneous and intravenous routes, for global markets. Dr. Reddy’s proposed rituximab biosimilar application has been accepted for review by the USFDA, EMA and MHRA.

Coya已经成功完成了第二阶段研究，并启动了DRL\U TC的第三阶段研究，DRL\U TC是其通过皮下和静脉途径提出的托珠单抗生物仿制药，用于全球市场。Reddy博士提出的利妥昔单抗生物仿制药申请已被美国FDA，EMA和MHRA接受审查。

Coya has also ramped up manufacturing capacity to support its global expansion plans..

科亚航空还提高了制造能力，以支持其全球扩张计划。。

About Dr. Reddy’s Laboratories Limited:

关于Reddy博士实验室有限公司：

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, it is committed to providing access to affordable and innovative medicines. Driven by its purpose of ‘Good Health Can’t Wait’, the company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

Reddy博士实验室有限公司（BSE:500124，NSE:DRREDDY，NYSE:RDY，NSEIFSC:DRREDDY）是一家全球制药公司，总部位于印度海得拉巴。它成立于1984年，致力于提供负担得起的创新药物。在“健康不能等待”的宗旨的推动下，该公司提供了一系列产品和服务，包括API、仿制药、品牌仿制药、生物仿制药和OTC。

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, Dr.

它的主要治疗领域是胃肠道，心血管，糖尿病，肿瘤学，疼痛管理和皮肤病学。其主要市场包括美国、印度、俄罗斯和独联体国家、中国、巴西和欧洲。作为一家拥有深厚科学历史的公司，他创造了多个行业第一。

Reddy’s continues to plan and invest in the businesses of the future. As an early adopter of sustainability and ESG actions, we released its first Sustainability Report in 2004. Its current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance.

Reddy's继续计划和投资未来的业务。作为可持续发展和ESG行动的早期采用者，我们于2004年发布了第一份可持续发展报告。其目前的ESG目标旨在为环境管理设定更高的标准；患者的获取和负担能力；多样性；和治理。

For more information, log on to: https://www.drreddys.com/..

For more information, log on to:https://www.drreddys.com/..

About Coya Therapeutics, Inc.

关于Coya Therapeutics，Inc。

Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system..

Coya Therapeutics，Inc.（纳斯达克股票代码：Coya）总部位于德克萨斯州休斯顿，是一家临床阶段生物技术公司，开发专有治疗方法，专注于调节性T细胞（“Tregs”）的生物学和潜在治疗优势，以靶向全身炎症和神经炎症。功能失调的Tregs是许多疾病的基础，包括神经退行性疾病，代谢性疾病和自身免疫性疾病，这种细胞功能障碍可能导致持续的炎症和氧化应激，导致免疫系统缺乏稳态。。

Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya’s 300 Series product candidates, COYA 301 and COYA 302, are biologic therapies intended to enhance Treg function and expand Treg numbers.

Coya的研究产品候选管道利用多种治疗方式，旨在恢复Tregs的抗炎和免疫调节功能。Coya的治疗平台包括Treg增强生物制剂，Treg衍生的外泌体和自体Treg细胞疗法。Coya的300系列候选产品Coya 301和Coya 302是旨在增强Treg功能和扩大Treg数量的生物疗法。

COYA 301 is a cytokine biologic for subcutaneous administration intended to enhance Treg function and expand Treg numbers in vivo, and COYA 302 is a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages.

COYA 301是一种用于皮下给药的细胞因子生物制剂，旨在增强Treg功能并扩大体内Treg数量，COYA 302是一种用于皮下和/或静脉内给药的生物组合，旨在增强Treg功能，同时消耗T效应子功能和活化的巨噬细胞。

These two mechanisms may be additive or synergistic in suppressing inflammation. For more information about Coya, please visit www.coyatherapeutics.com..

这两种机制在抑制炎症方面可能是相加的或协同的。有关Coya的更多信息，请访问www.coyatherapeutics.com。。

Forward-Looking Statements

前瞻性声明

This press release contains “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities.

本新闻稿包含基于管理层的信念和假设以及管理层目前可获得的信息的“前瞻性”声明。前瞻性陈述包括除本演示文稿中包含的历史事实陈述以外的所有陈述，包括有关我们当前和未来财务业绩、业务计划和目标、当前和未来临床和临床前开发活动、我们正在进行和计划中的临床试验的时间和成功以及相关数据的信息，我们临床试验和相关数据的发布时间、更新和结果，我们获得和维持监管批准的能力，我们候选产品的潜在治疗效益和经济价值，竞争地位，行业环境和潜在市场机会。

The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements..

“相信”、“可能”、“会”、“估计”、“继续”、“预期”、“打算”、“预期”等词语以及类似的表达旨在识别前瞻性陈述。。

Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the impact of COVID-19; the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; ; and our estimates regarding expenses, future revenue, capital .

前瞻性陈述受到已知和未知风险、不确定性、假设和其他因素的影响，包括但不限于与新型冠状病毒影响相关的风险；我们的产品候选开发活动以及正在进行和计划进行的临床试验的成功，成本和时间安排；我们计划开发和商业化靶向治疗药物；我们的临床前或临床试验中患者登记和给药的进展；我们的候选产品在临床试验中达到适用终点的能力；我们候选产品的安全概况；我们的临床试验数据支持营销应用的潜力，以及这些事件的时间安排；我们获得运营资金的能力；我们候选产品的开发和商业化；获得和维持监管批准的时间和能力；我们候选产品的市场接受率和程度以及临床实用性；我们候选产品的市场规模和增长潜力，以及我们服务这些市场的能力；我们的商业化、营销和制造能力和战略；与第三方就我们候选产品的商业化达成的未来协议；我们对获得和维持知识产权保护能力的期望；我们对第三方制造商的依赖；已经或可能获得的竞争疗法或产品的成功；我们吸引和留住关键科学或管理人员的能力；我们能够确定与我们的商业目标一致的具有重大商业潜力的其他候选产品；以及我们对费用、未来收入和资本的估计。

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs.

我们的这些前瞻性陈述主要基于我们目前对未来事件和趋势的预期和预测，我们认为这些事件和趋势可能会影响我们的财务状况、运营结果、业务战略、短期和长期业务运营和目标以及财务需求。

Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make.

此外，我们的经营环境竞争激烈，变化迅速，新的风险可能会不时出现。我们的管理层不可能预测所有风险，也不可能评估所有因素对我们业务的影响，也不可能评估任何因素或因素组合可能导致实际结果与我们可能做出的任何前瞻性陈述中所包含的结果存在重大差异的程度。

In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur.

鉴于这些风险、不确定性和假设，本文讨论的前瞻性事件和情况可能不会发生，实际结果可能与前瞻性声明中预期或暗示的结果存在重大不利差异。虽然我们的管理层认为我们的前瞻性声明中反映的期望是合理的，但我们不能保证前瞻性声明中描述的未来结果、活动水平、绩效或事件和情况能够实现或发生。

We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise..

我们没有义务公开更新任何前瞻性声明，无论是书面的还是口头的，无论是由于新信息、未来发展还是其他原因。。

1 https://www.businesswire.com/news/home/20230317005028/en/Coya-Therapeutics-Inc.-Announces-an-Agreement-with-Dr.-Reddy%E2%80%99s-Laboratories-Ltd.-to-License-its-proposed-biosimilar-Abatacept-for-the-Development-and-Commercialization-of-COYA-302-for-the-Treatment-of-Neurodegenerative-Diseases

1https://www.businesswire.com/news/home/20230317005028/en/coya-therapeutics-inc.-announces-an-agreement-with-dr.-reddy%e2%80%99s-实验室有限公司-to-License-its-proposed-biosimilar-Abatacept-for-the-Development-and-Commercialization-of-COYA-302-for-the-Treatment-of-neur退行性疾病